[go: up one dir, main page]

NO20083160L - Methods for obtaining immortalized anitbody secreting cells - Google Patents

Methods for obtaining immortalized anitbody secreting cells

Info

Publication number
NO20083160L
NO20083160L NO20083160A NO20083160A NO20083160L NO 20083160 L NO20083160 L NO 20083160L NO 20083160 A NO20083160 A NO 20083160A NO 20083160 A NO20083160 A NO 20083160A NO 20083160 L NO20083160 L NO 20083160L
Authority
NO
Norway
Prior art keywords
methods
cells
human
anitbody
secrete
Prior art date
Application number
NO20083160A
Other languages
English (en)
Norwegian (no)
Inventor
Marianne Murphy
Ada Funaro
Gianni Garotta
Original Assignee
Ribovax Biotechnologies Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribovax Biotechnologies Sa filed Critical Ribovax Biotechnologies Sa
Publication of NO20083160L publication Critical patent/NO20083160L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20083160A 2005-12-16 2008-07-15 Methods for obtaining immortalized anitbody secreting cells NO20083160L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2005056871 2005-12-16
PCT/EP2006/069780 WO2007068758A1 (fr) 2005-12-16 2006-12-15 Procédés permettant d'obtenir des cellules sécrétant des anticorps immortalisés

Publications (1)

Publication Number Publication Date
NO20083160L true NO20083160L (no) 2008-09-10

Family

ID=36685876

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083160A NO20083160L (no) 2005-12-16 2008-07-15 Methods for obtaining immortalized anitbody secreting cells

Country Status (19)

Country Link
US (1) US8338172B2 (fr)
EP (1) EP1974020B1 (fr)
JP (2) JP5431730B2 (fr)
KR (1) KR101508945B1 (fr)
CN (1) CN101374944B (fr)
AT (1) ATE513034T1 (fr)
AU (1) AU2006325236B2 (fr)
BR (1) BRPI0619908A2 (fr)
CA (1) CA2633601C (fr)
DK (1) DK1974020T3 (fr)
EA (1) EA019505B1 (fr)
ES (1) ES2367322T3 (fr)
IL (1) IL192095A0 (fr)
NO (1) NO20083160L (fr)
NZ (1) NZ569816A (fr)
PL (1) PL1974020T3 (fr)
PT (1) PT1974020E (fr)
WO (1) WO2007068758A1 (fr)
ZA (2) ZA200806094B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2398783A (en) 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
US8202518B2 (en) 2007-07-04 2012-06-19 Ribovax Biotechnologies S.A. Antibodies against human cytomegalovirus (HCMV)
EP3293269A1 (fr) * 2007-08-03 2018-03-14 MUSC Foundation For Research Development Anticorps monoclonaux humains et procédés de production
US20110171233A1 (en) * 2007-08-22 2011-07-14 Ribovax Biotechnologies S.A. Antibodies Against Human Cytomegalovirus (HCMV)
EP2352759B1 (fr) 2008-07-16 2017-11-01 Institute for Research in Biomedicine Anticorps neutralisant le cytomégalovirus humain et utilisation de ceux-ci
US8703486B2 (en) 2008-09-23 2014-04-22 UNIVERSITé LAVAL Method for polyclonal immunoglobulin G production by human B cells
US8568719B2 (en) 2009-08-13 2013-10-29 Crucell Holland B.V. Antibodies against human respiratory syncytial virus (RSV) and methods of use
JP6174320B2 (ja) 2009-11-17 2017-08-02 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント ヒトヌクレオリンに対するヒトモノクローナル抗体
JP5833565B2 (ja) 2009-12-23 2015-12-16 ４−アンティボディ・アクチェンゲゼルシャフト４−Ａｎｔｉｂｏｄｙ Ａｇ ヒトサイトメガロウイルスに対する結合メンバー
EP2400298B1 (fr) * 2010-05-28 2013-08-14 F.Hoffmann-La Roche Ag Procédé de culture de lymphocyte simple et production d'anticorps spécifque
CA3062786C (fr) 2010-07-09 2022-04-19 Janssen Vaccines & Prevention B.V. Anticorps anti-virus respiratoire syncytial (rsv) humain et procedes d'utilisation
CN102839152A (zh) * 2011-06-20 2012-12-26 中国科学院上海生命科学研究院 一种快速高效获得抗原特异性b细胞的方法
WO2013000982A1 (fr) 2011-06-27 2013-01-03 Vivalis Procédé de criblage de cellules
US9757458B2 (en) * 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
AU2013206788B2 (en) 2011-12-28 2017-11-30 Immunoqure Ag Method of providing monoclonal auto-antibodies with desired specificity
US10131709B2 (en) 2011-12-28 2018-11-20 Immunoqure Ag Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
WO2014093786A1 (fr) * 2012-12-14 2014-06-19 Abbvie, Inc. Méthodes pour augmenter l'efficacité de génération d'hybridomes
CA2896908A1 (fr) * 2013-01-03 2014-07-10 Merck Patent Gmbh Procede de production d'anticorps secretables par expression dans saccharomyces cerevisiae
WO2015001047A1 (fr) 2013-07-03 2015-01-08 Immunoqure Ag Procédé donnant des anticorps anti-cytokine humaine à usage pharmaceutique
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
EP3562936B1 (fr) * 2017-01-02 2024-05-22 F. Hoffmann-La Roche AG Procédé de culture de lymphocyte b
JP2020515522A (ja) * 2017-01-27 2020-05-28 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド 免疫応答を誘導するヘルペスウイルスエンベロープタンパク質の組み合わせのワクチン組成物
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN111647566A (zh) * 2019-07-10 2020-09-11 广州医科大学附属第一医院 一种高滴度eb病毒的制备方法、eb病毒永生化记忆性b细胞的方法与应用
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
EP4263600A1 (fr) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Systèmes récepteurs antigéniques chimériques ayant une spécificité de récepteur adaptable
CN120239745A (zh) * 2022-12-06 2025-07-01 北山拉贝斯株式会社 永生化细胞的制造方法
CN117230258B (zh) * 2023-11-10 2024-04-09 苏州驾玉生物医药有限公司 一种提高灵敏度的培养扩增联合pcr的eb病毒检测方法
CN119285758B (zh) * 2024-10-31 2025-07-01 上海百英生物科技股份有限公司 一种基于b细胞永生化的单个b细胞抗体开发方法及其应用
CN120272432A (zh) * 2025-03-25 2025-07-08 佛山市妇幼保健院 一种脊髓性肌萎缩症质控品及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997764A (en) * 1987-04-23 1991-03-05 New York University Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors
WO1991004336A1 (fr) * 1989-09-19 1991-04-04 Centocor, Inc. Procede d'amelioration de la production d'anticorps monoclonaux humains
EP0440147B2 (fr) 1990-02-01 2014-05-14 Siemens Healthcare Diagnostics Products GmbH Préparation et utilisation de banques de gènes d'anticorps humains (bibliothèques d'anticorps humains)
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6399384B1 (en) * 1999-09-17 2002-06-04 Reneuron Limited Conditional immortalization of cells
FR2817875B1 (fr) * 2000-12-07 2005-03-18 Technopharm Procede de preparation d'un anticorps monoclonal humain, de fragments de celui-ci ou d'anticorps comprenant de tels fragments, les anticorps ainsi obtenus et leur utilisation
GB2398783A (en) * 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
AU2004215125B2 (en) * 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
WO2007063415A2 (fr) * 2005-08-23 2007-06-07 Iq Corporation Procedes de production de lymphocytes b stables

Also Published As

Publication number Publication date
CN101374944B (zh) 2012-02-08
AU2006325236A1 (en) 2007-06-21
KR20080097181A (ko) 2008-11-04
EP1974020B1 (fr) 2011-06-15
CN101374944A (zh) 2009-02-25
WO2007068758A1 (fr) 2007-06-21
AU2006325236B2 (en) 2011-11-10
EP1974020A1 (fr) 2008-10-01
HK1127783A1 (en) 2009-10-09
ZA200904907B (en) 2010-04-28
US8338172B2 (en) 2012-12-25
EA019505B1 (ru) 2014-04-30
IL192095A0 (en) 2008-12-29
ATE513034T1 (de) 2011-07-15
JP5431730B2 (ja) 2014-03-05
PT1974020E (pt) 2011-08-26
BRPI0619908A2 (pt) 2011-10-25
NZ569816A (en) 2011-10-28
DK1974020T3 (da) 2011-10-03
PL1974020T3 (pl) 2011-11-30
KR101508945B1 (ko) 2015-04-08
JP2009519026A (ja) 2009-05-14
CA2633601A1 (fr) 2007-06-21
EA200870062A1 (ru) 2009-04-28
JP2013255515A (ja) 2013-12-26
US20090270268A1 (en) 2009-10-29
ES2367322T3 (es) 2011-11-02
ZA200806094B (en) 2009-06-24
CA2633601C (fr) 2015-06-30

Similar Documents

Publication Publication Date Title
NO20083160L (no) Methods for obtaining immortalized anitbody secreting cells
US12351825B2 (en) Soluble antibody complexes for T cell or NK cell activation and expansion
Cao et al. B. 1.1. 529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes
Tsioris et al. Neutralizing antibodies against West Nile virus identified directly from human B cells by single-cell analysis and next generation sequencing
PH12020500160A1 (en) Reagents for expanding cells expressing recombinant receptors
EA202190608A1 (ru) Однодоменные анти-bcma антитела и их применение
MX2010007729A (es) Vectores de expresion de mamifero mejorados y uso de los mismos.
DE60232895D1 (de) Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwort
MX2021014966A (es) Anticuerpos anti-cd3 dependientes de ph modificados geneticamente y metodos para su generacion y uso.
Dang et al. Soluble CD27 induces IgG production through activation of antigen‐primed B cells
WO2009035738A3 (fr) Utilisation d'une analyse elispot de cellules sécrétrices d'anticorps pour évaluer les réponses des anticorps suite à leur exposition à un antigène
WO2021226289A3 (fr) Compositions et procédés pour la reprogrammation de tcr au moyen de protéines de fusion spécifiques cd70
Correa et al. Evaluation of antigen-conjugated fluorescent beads to identify antigen-specific B cells
Vasquez et al. Rapid proliferation and differentiation of a subset of circulating IgM memory B cells to a CpG/cytokine stimulus in vitro
Scholzen et al. Expansion of IgG+ B-cells during mitogen stimulation for memory B-cell ELISpot analysis is influenced by size and composition of the B-cell pool
WO2009045075A3 (fr) Anticorps monoclonal spécifique des cellules souches embryonnaires humaines, hybridome sécrétant ce dernier et procédé permettant de détecter ou d'isoler une cellule souche embryonnaire non différenciée
ATE533788T1 (de) Antikörper gegen cd44vra und methoden zu ihrer verwendung
Zhang et al. Analysis of the Heterogeneity of CD4+ CD25+ T Cell TCR β CDR3 Repertoires in Breast Tumor Tissues, Lung Metastatic Tissues, and Spleens from 4T1 Tumor‐Bearing BALB/c Mice
DE602005022757D1 (de) Verwendung von endosialinbindenden proteinen zum isolieren endosialinpositiver zellen
Azimi CAR Pooling: High throughput screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies
Jackson et al. Distinct Immunological Landscapes of HCMV-Specific T Cells in Bone Marrow and Peripheral Blood
WO2006089002A3 (fr) Methode de criblage a haut rendement d'anticorps et de proteines induisant l'apoptose
Manna et al. Autologous crossmatches: How useful are they in the evaluation of positive donor flow cytometric crossmatches?
UA72439U (ru) Тест-система иммуноферментная для качественного и полуколичественного определения антител класса igg к вирусам простого герпеса 2 типа, унифицированная "dia-hsv 2-igg-u"
UA72423U (ru) ИММУНОФЕРМЕНТНАЯ ТЕСТ-СИСТЕМА ДЛЯ КОЛИЧЕСТВЕННОГО АНАЛИЗА И ОПРЕДЕЛЕНИЯ АВИДНОСТИ АНТИТЕЛ КЛАССА IgG ВИРУСА КРАСНУХИ (DIA-RUBELLA-IGG-AV)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application